HER2-Positive Breast Cancer | Topics

Around the Practice: January 2021 Virtual Tumor Board
January 19, 2021

Register for CancerNetwork's live, interactive event featuring leaders in oncology reviewing and discussing patient cases in breast cancer.

FDA Action Moves ARX788 Forward in the Treatment of HER2-Positive Breast Cancer
January 05, 2021

ARX788 received a nod from the FDA early in 2021 based on promising preclinical and phase 1 trial data demonstrating its efficacy in patients with HER2-positive breast cancer following progression on other agents.

FDA Approves Margetuximab-cmkb, Chemo Combo for Pretreated Metastatic HER2+ Breast Cancer
December 16, 2020

The FDA approved margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens, at least 1 of which was for metastatic disease.